Peran Phosphatase Regenerating Liver-3 dan Vascular Endothelial Growth Factor dalam Progresivitas Kanker Ovarium Epitelial

Sharvianty Arifuddin


Abstract


Tujuan: Mengetahui peran phosphatase regenerating liver-3 (PRL-3) dan vascular endothelial growth factor (VEGF) dalam progresivitas kanker ovarium.
Metode: Penelitian dilakukan pada penderita kanker ovarium di beberapa rumah sakit jejaring Fakultas Kedokteran Universitas Hasanuddin Makassar. Pengambilan sampel dilaksanakan secara consecutive sampling. Pengambilan cairan ascites dan jaringan tumor pada saat operasi dilakukan untuk pemeriksaan hematoksilin eosin dan immunohistokimia, dan pemeriksaan mRNA dengan RT-PCR. Pemeriksaan hematoksilin eosin untuk mengukur histopatologi. Pemeriksaan imunohistokimia dilakukan untuk mengetahui ekskpresi PRL-3 dan VEGF. RT-PCR digunakan untuk melakukan pemeriksaaan mRNA PRL-3. Data dianalisis dengan uji chi-square dan analisis korelasi Spearman pada taraf signifikansi 5%.
Hasil: Hasil diperoleh 38 subyek penelitian yang terdiri dari 26,3% stadium awal dan 73,7% stadium lanjut. Ekspresi PRL-3 tidak berbeda secara bermakna berdasarkan stadium, derajat diferensiasi, dan lokasi tumor dengan p > 0,05. Ekspresi PRL-3 pada kanker ovarium primer yang disertai metastasis lebih tinggi secara bermakna dibandingkan dengan kanker ovarium primer tanpa metastasis (p<0,05). Ekspresi VEGF tidak berbeda secara bermakna berdasarkan stadium, derajat diferensiasi, kanker ovarium primer, dan lokasi tumor dengan p > 0,05. Ada korelasi positif yang bermakna antara ekspresi PRL-3 dengan VEGF pada kanker ovarium epitelial (p<0,05).
Kesimpulan: Tingginya ekspresi PRL-3 meningkatkan ekspresi VEGF dan progresivitas kanker ovarium epitelial.

The Role of Phosphatase Regenerating Liver-3 and Vascular Endothelial Growth Factors in The Progressivity of Ovarium Epithelial Cancer

Abstract
Objective: To determine the role of liver regenerating phosphatase-3 (PRL-3) and vascular endothelial growth factor (VEGF) in the progression of ovarian cancer.
Method: This study was conducted on ovarian cancer patients in several teaching hospitals in the Department of Obgyn, Faculty of Medicine, Hasanuddin University, Makassar. Sampling was carried out by consecutive sampling. Sampling of ascites fluid and tumor tissue at the time of surgery was carried out for hematoxylin eosin and immunohistochemical examination, and for mRNA examination by RT-PCR. Eosin hematoxylin examination to measure histopathology. Immunohistochemical examination was carried out to determine the expression of PRL-3 and VEGF. RT-PCR was used to examine PRL-3 mRNA. Data were analyzed by chi-square test and Spearman correlation analysis at 5% significance level.
Results: The results obtained were 38 research subjects consisting of 26.3% early stage and 73.7% advanced stage. PRL-3 expression did not differ significantly based on the stage, degree of differentiation, and tumor location with p > 0.05. PRL-3 expression in primary ovarian cancer with metastases was significantly higher than in primary ovarian cancer without metastases (p<0.05). VEGF expression did not differ significantly based on stage, degree of differentiation, primary ovarian cancer and tumor location with p > 0.05. There was a significant positive correlation between PRL-3 expression and VEGF in epithelial ovarian cancer (p<0.05).
Conclusion: The high expression of PRL-3 increases the expression of VEGF and the progression of epithelial ovarian cancer.

Key words: ovarian cancer, phosphatase regenerating liver-3, vascular endothelial growth factor


Keywords


kanker ovarium, phosphatase regenerating liver-3, vascular endothelial growth factor

Full Text:

PDF

References


Fleming G, Ronnett B, Seidman J, Zaino R, Rubin S. Epithelial Ovarian Cancer. In: RBarakat R, Markman M, Randall ME, editors Principles and Practice of Gynecologic Oncology 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. hal. 623–81.

Vanderhyden B, Shaw T, Garson K, Tonary A. Ovarian Carcinogenesis. In: In: Leung PCK and Adashi EY, editors The Ovary 2nd ed. California: Elseiver; 2004. hal. 591–612.

Jemal A, Bray F, Ferlay J. Global Cancer Statistics: 2011. CA Cancer J Clin [Internet]. 1999;49(2):1,33-64. Tersedia pada: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10200776

Cvetkovic D, Connolly D, Hamilton T. Molecular Biology and Molecular Genetics Of Ovarian, Fallopian Tube and Primary Peritoneal Cancer. In: Gershenson DM Gynecologic Cancer Controversies in Management. Philadelphia: Elsevier; 2004.

Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):12–27.

Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4–7.

Gómez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A. Angiogenesis and ovarian cancer. Clin Transl Oncol. 2009;11(9):564–71.

Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, et al. Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun. 2001;283(5):1061–8.

Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St. Croix B, et al. A phosphatase associated with metastasis of colorectal cancer. Science (80- ). 2001;294(5545):1343–6.

Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003;63(11):2716–22.

Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, et al. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006;66(19):9625–35.

Ming J, Liu N, Gu Y, Qiu X, Wang EH. PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology. 2009;41(2):118–26.

Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 2005;11(19 I):6835–9.

Reich R, Hadar S, Davidson B. Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci. 2011;12(2):1133–45.

Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, et al. Prognostic significance of phosphatase of regenerating liver-3 expression in ovarian cancer. Pathol Oncol Res. 2009;15(4):555–60.

Liu H, Al-aidaroos AQO, Wang H, Guo K, Li J, Zhang HF, et al. PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells. BMC Cancer. 2013;13.

Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 2004;10(21):7318–28.

Wang H, Quah SY, Jing MD, Manser E, Jing PT, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67(7):2922–6.

Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: Close correlation with invasion and metastasis. Pathobiology. 2004;71(4):176–84.

Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2007;106(1):221–32.

Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of Angiogenesis- Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice. J Natl Cancer Inst. 1998;90(6):2013–5.

Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries. Cancer Res. 1994;54(1):276–80.




DOI: http://dx.doi.org/10.24198/obgynia/v6.n2.526

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


     
     

Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
  Web Analytics
  View My Stat